6640--Multiple Sclerosis Disease Activity Testing Services for the John D. Dingell VA Medical Center in Detroit, MI
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), John D. Dingell VAMC, intends to award a firm fixed-price contract for Multiple Sclerosis Disease Activity Testing Services in Detroit, MI. The government plans a sole source negotiation with Octave Bioscience, Inc. due to the proprietary nature of their tests. Responses from other interested parties demonstrating competitive advantage are due by May 27, 2026.
Scope of Work
This requirement is for providing specific reference laboratory tests, specifically the proprietary Octave MS Disease Activity (MSDA) blood biomarker assay. The contractor will be responsible for all supplies, labor, knowledge, techniques, supervision, test equipment, and analysis necessary to perform these tests as requested by the VA Ann Arbor Healthcare System. The MSDA test measures 18 protein biomarkers to produce a disease activity score and pathway sub-scores, supporting clinical management of Veterans with Multiple Sclerosis.
Contract & Timeline
- Contract Type: Firm Fixed Price
- Duration: One (1) year from contract award date.
- Set-Aside: Intended Sole Source to Octave Bioscience, Inc.
- NAICS Code: 541380 (Testing Laboratories and Services)
- Size Standard: $19.0 million
- Response Due: May 27, 2026, 12:00 PM EST
- Published: May 22, 2026
Submission & Evaluation
This procurement will be conducted under FAR Part 13. The Government's intent is to negotiate on a sole source basis with Octave Bioscience, Inc. due to the proprietary nature of their testing services. A sources sought notice was previously published (36C25026Q0548). Any response to this notice must provide clear and convincing evidence that competition would be advantageous to the Government. A determination not to compete is solely at the Government's discretion.
Additional Notes
Responses must be submitted via email only to Cierra.Joshua@va.gov. The place of performance for specimen collection is the John D. Dingell VA Medical Center in Detroit, MI, with testing at the contractor's CLIA-certified laboratory.